Seres Therapeutics Presents New Preclinical Data Supporting the Development of SER-401 for Immuno-Oncology at the 2019 American Association for Cancer Research Annual Meeting
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that new preclinical data supporting the development of microbiome therapeutics for immuno-oncology (poster title “Leveraging gut microbiota networks to impact tumor immunotherapy”)1 will be presented by Sceneay et al. at the 2019 American Association for Cancer Research Annual Meeting (AACR) in Atlanta, Georgia. The data presented provide new insights on the potential mechanism by which Seres’ microbiome therapies, including the Company’s SER-401 program, could improve outcomes of cancer patients treated with immune checkpoint inhibitors. “The novel data presented at AACR provide mechanistic insights into the biological activity of our microbiome therapeutic candidates to augment immune checkpoint inhibitors,” said Matthew Henn, Ph.D., Chief Scientific Officer and Executive Vice President at Seres. “The valuable
Show less
Read more
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT [Yahoo! Finance]Yahoo! Finance
- Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCTBusiness Wire
- Global Microbiome Manufacturing Industry Research 2024: A $187 Billion Market by 2035 with Close to 170 Trials Evaluating Microbiome Therapeutics to Treat Infectious Diseases and Oncological Disorders [Yahoo! Finance]Yahoo! Finance
- Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now [Yahoo! Finance]Yahoo! Finance
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
MCRB
Earnings
- 11/2/23 - Beat
MCRB
Sec Filings
- 4/23/24 - Form 8-K
- 4/8/24 - Form 4
- 4/8/24 - Form 4
- MCRB's page on the SEC website